Sandra Klein

Prof. Dr. Sandra Klein

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2014 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
EKEdmund S. Kostewicz
Edmund S. Kostewicz
BABertil Abrahamsson
Bertil Abrahamsson
MBMarcus Brewster
Marcus Brewster
JBJoachim Brouwers
Joachim Brouwers
JBJames Butler
James Butler
PAPatrick Augustijns
Patrick Augustijns

1 April 2020 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
CSCordula Stillhart
Cordula Stillhart
Katarina M VučićevićKatarina M Vučićević
Katarina M Vučićević
PAPatrick Augustijns
Patrick Augustijns
ABAbdul W Basit
Abdul W Basit
HBHannah Batchelor
Hannah Batchelor
AMAnette Mullertz
Anette Mullertz
The release and absorption profile of an oral medication is influenced by the physicochemical properties of the drug and its formulation, as well as by the anatomy and physiology of the gastrointestinal (GI) tract. During drug development the bioavailability of a new drug is typically assessed in early clinical studies in a healthy adult population. However, many disease conditions are associated with an alteration of the anatomy and/or physiology of the GI tract. The same holds true for some subpopulations, such as paediatric or elderly patients, or populations with different ethnicity. The variation in GI tract conditions compared to healthy adults can directly affect the kinetics of drug absorption, and thus, safety and efficacy of an oral medication. This review provides an overview of GI tract properties in special populations compared to healthy adults and discusses how drug absorption is affected by these conditions. Particular focus is directed towards non-disease dependent conditions (age, sex, ethnicity, genetic factors, obesity, pregnancy), GI diseases (ulcerative colitis and Crohn's disease, celiac disease, cancer in the GI tract, Roux-en-Y gastric bypass, lactose intolerance, Helicobacter pylori infection, and infectious diseases of the GI tract), as well as systemic diseases that change the GI tract conditions (cystic fibrosis, diabetes, Parkinson's disease, HIV enteropathy, and critical illness). The current knowledge about GI conditions in special populations and their impact on drug absorption is still limited. Further research is required to improve confidence in pharmacokinetic predictions and dosing recommendations in the targeted patient population, and thus to ensure safe and effective drug therapies.

1 June 2014 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
HBHannah Batchelor
Hannah Batchelor
NFNikoletta Fotaki
Nikoletta Fotaki
SKSandra Klein
Sandra Klein

1 April 2013 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
TTThomas Taupitz
Thomas Taupitz
JDJennifer B. Dressman
Jennifer B. Dressman
CBCharles M. Buchanan
Charles M. Buchanan
SKSandra Klein
Sandra Klein

1 May 2004 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SKSandra Klein
Sandra Klein
JBJames Butler
James Butler
JHJohn M. Hempenstall
John M. Hempenstall
CRChristos Reppas
Christos Reppas
JDJennifer B. Dressman
Jennifer B. Dressman
To better predict food effects on the bioavailability/bioequivalence of drugs and drug products from in-vitro data, a dissolution medium that simulates the initial composition of the postprandial stomach was developed. First, the physical parameters of two homogenized standard breakfasts often administered to assess food effects in pharmacokinetic studies were measured. These included pH, buffer capacity, osmolality, surface tension and viscosity. Subsequently, the match of the physical parameters of several commercially available liquid meals, including long-life milk, Ensure and Ensure Plus to those of the breakfasts was evaluated. Of the three liquid meals studied, Ensure Plus had the closest physicochemical behaviour to that of homogenized standard breakfasts. By increasing the viscosity of Ensure Plus with 0.45% pectin, it was possible to obtain a medium that closely resembles the FDA standard breakfast.